Desmoid tumors can present management challenges due to their unpredictable behavior. Steven I. Robinson, MBBS, an associate professor of oncology and medical oncologist at the Ma ...

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP ...

A machine learning model enhances treatment decisions for hepatocellular carcinoma, optimizing survival outcomes through ...

2. Ferrarotto R, Anderson I, Medgyasszay B, et al. Trilaciclib prior to chemotherapy reduces the usage of supportive care ...

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell ...

Innovative treatments like JAK2 inhibitors and bispecific antibodies show promise in overcoming immunotherapy resistance in non-small cell lung cancer.

An expert discusses emerging frontline treatments for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting the ...

Welcome to this week's edition of The Targeted Pulse. This week in oncology, we saw a number of significant developments, ...

Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...

Berry and colleagues from the Institute for Healthcare Improvement and Henry Ford Health Detroit argue that deep, ...